Cadrenal weighs asset sales or reverse merger as cash runs short
Alpha Vantage · Stock Titan · · AI-summarised by FinFlash
Cadrenal Therapeutics posted a $7.1 million net loss for the nine months ended September 30, 2026, and said its $2.7 million in cash is insufficient beyond Q1 2027, raising substantial doubt about its ability to continue as a going concern. The board has begun a strategic review advised by Tungsten Advisors.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.